1. Scrip
  2. >>Digital Technologies
  3. >>AI

Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy

Bullish Sector Outlook As Technological Progress Drives Growth

 
• By Eleanor Malone

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.

Scrip Asks, Part 5, Feature image
• Source: Shutterstock

SCRIP ASKS…What Does 2021 Hold For Biopharma?

A broad survey of the industry’s expectations for the year to come.

Every December, Scrip asks industry leaders and experts to share their expectations for the year to come. With responses from more than 200 professionals, Scrip Asks…What Does 2021 Hold For Biopharma? provides an unprecedented insight into the biopharma universe’s collective crystal ball.

The full list of installments:

Industry leaders and experts envisage positive change in the biopharma sector over the coming year, fueled by advances in science and data processing

Last year was strong for both financing and deal making, reflecting the global investment in life sciences in the face of the COVID-19 pandemic as well as the continuation of the positive trend for those developing cutting edge technologies in fields such as immuno-oncology and gene therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

More from Digital Technologies

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 
• By Anju Ghangurde

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By Vibha Ravi

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

 
• By Alaric DeArment

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.